Articles tagged "Kidney transplantation"

2019 American Transplant Congress
Late Onset J C Virus Allograft Nephropathy
M. Samra, I. Tang, S. Setty
University of Illinois Health, Chicago, IL
*Purpose: JC virus(JCV) is a member of the Polyomaviridae family. Few studies have been published regarding the replication of JCV in transplant recipients. The incidence…
2019 American Transplant Congress
Integration Of Business Intelligence (BI) Solution In Tertiary Renal Transplant Centre To Drive Clinical Decisions.
M. Heer, S. Yausis, P. R. Trevillian
Newcastle Transplant Unit, John Hunter Hospital, Newcastle, Australia
*Purpose: The future of medicine will be enabled by big data. With the promise of data-driven knowledge and decision-making, innovative big-data projects are ongoing in…
2019 American Transplant Congress
Donor-Derived Cell-Free DNA (dd-cfDNA) Course after Rejection in Pediatric Kidney Transplant Recipients
R. D. Swinford¹, A. M. De Golovine¹, C. Bell¹, A. Pai¹, A. R. Edwards¹, S. Connor², J. S. Bynon¹
¹Pediatrics, UTHealth, McGovern Medical School, University of Texas at Houston, Houston, TX, ²Transplantation, Memorial Hermann Hospital, Houston, TX
*Purpose: Accurate identification of successful treatment for rejection (R) without repeat kidney biopsy (KB) in kidney transplantation is an unmet need. The few existing biomarkers…
2019 American Transplant Congress
Impact Of Transplant Center And Regional Characteristics On Racial Disparities On Readmission After Kidney Transplantation
J. Hogan¹, K. Li¹, R. Zhang¹, J. Sun², A. B. Adams¹, R. E. Patzer¹
¹Transplant Research Center, Department of Surgery, Emory University, ATLANTA, GA, ²College of Computing, Georgia Technology Institute, ATLANTA, GA
*Purpose: Hospital readmission rates after kidney transplant (KTx) are high and readmission is associated with graft failure and mortality. Previous studies have reported that African…
2019 American Transplant Congress
Hepatitis C Antibody Positive (HCV Ab+)/Nucleic Acid Test Negative (NAT -) Deceased Donor Kidney Transplantation into Hepatitis C Negative (HCV -) Recipients: Is It Safe?
Y. Taehwan, A. Rajab, G. Bumgardner, t. Pesavento, R. Daloul, A. Michaels, K. Washburn, A. El-Hinnawi
Ohio State University, Columbus, OH
*Purpose: Kidneys procured from HCV Ab+/NAT - are not routinely used due to concern for HCV transmission into recipients. However, there has been no report…
2019 American Transplant Congress
Post-Transplant Cancer and Graft Failure in Kidney Transplant Recipients
J. Kim, J. Ha, S. Min, H. Lee, Y. Kim, S. Han
Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: As the long-term patient survival and graft survival rate are gradually increasing in kidney transplant (KT) recipients, the importance of cancer occurrence and proper…
2019 American Transplant Congress
Immune Cells Composition of Humanized Mouse Kidney Compared to Normal Human Kidney
S. Noel¹, J. T. Kurzhagen¹, S. Lee¹, M. Sadasivam², A. R. Hamad², P. M. Pierorazio³, H. Rabb¹
¹Medicine, Johns Hopkins University, Baltimore, MD, ²Pathology, Johns Hopkins University, Baltimore, MD, ³Urology, Johns Hopkins University, Baltimore, MD
*Purpose: Most clinical studies fail in spite of promising mouse studies, in part due to fundamental differences between mice and human responses. Attempts have been…
2019 American Transplant Congress
Bcl-2 Inhibition with Venetoclax Promotes Induction of Mixed Chimerism and Renal Allograft Tolerance without Severe Myelosuppression in Non-Human Primate
H. Sasaki¹, D. Ma¹, T. Oura¹, A. Dehnadi¹, I. Rosales², B. Cosimi¹, P. Cippa³, T. Fehr³, T. Kawai¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²Pathology, Massachusetts General Hospital, Boston, MA, ³Medicine, University of Zurich, Zurich, Switzerland
*Purpose: Specific Bcl-2 inhibition has been shown to promote mixed chimerism and skin allograft tolerance without myelosuppressive conditioning in murine models. To extend this approach…
2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamsons, C. Myers, K. Lim, J. Choi, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…
2019 American Transplant Congress
Impact of Immunosuppressive Drug Withdrawal on Persistent Mixed Chimerism in Recipients of HLA Haplo-Identical Kidney and Hematopoietic Cell Transplants
S. Busque, J. Scandling, R. Lowsky, J. Shizuru, E. Meyer, K. Jensen, A. Shori, R. Hoppe, E. Engleman, S. Strober
Stanford University School of Medicine, Stanford, CA
*Purpose: We assessed the impact of the hematopoietic cell dose and the immunosuppressive drug (IS) withdrawal on the persistence of mixed chimerism after combined HLA…